Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- The patient is between 3 and 18 years old and has a suspected brain tumour for which they are having brain surgery
- The patient has not previously had a bone marrow transplant or similar blood-related procedures that could affect genetic testing results
- The patient has not received any cancer treatments — such as chemotherapy, radiation, or targeted therapy — before the surgery involved in joining this trial
- The patient's family or legal guardian has signed a consent form agreeing to take part
Who may not be able to join:
- After surgery, if testing confirms the condition is not a tumour — for example, if it turns out to be a structural abnormality, inflammation, or a condition affecting the nervous system's protective coating — the patient would not continue in the trial
- There is not enough tumour tissue or blood sample collected during surgery to carry out the tests required by the trial
- The patient has serious health conditions, active widespread infection, or unstable blood circulation that make it unsafe to collect the biological samples needed for the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 0555662631
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Single Nucleotide Variants (SNV); Number of copy number variations (CNVs); Number of triplet expansions; Number of structural variants (SVs); Morphological description of three-dimensional models derived from the tumour; Vitality of three-dimensional models derived from the tumour; Proliferative activity of three-dimensional models derived from the tumour; Percentage of residual cell vitality after drug treatment; Dose-response curves for each drug tested
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.